# A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)

> **NCT07401875** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 35 (estimated)

## Conditions studied

- Phase 1b
- HC-7366
- SHARK
- Kidney Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** HC-7366
- **DRUG:** ipilimumab

## Key facts

- **NCT ID:** NCT07401875
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-24
- **Primary completion:** 2027-11-30
- **Final completion:** 2029-11-30
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07401875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07401875, "A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07401875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*